Dr Sven Rohmann presented on behalf of Biotec Pharmacon at BIO-Europe Spring 2010 in Barcelona. The presentation took place at March 9, 12:30, under the AutoImmune/Inflammation Section.
Biotec Pharmacon is re-establishing the platform for pharmaceutical development of Soluble Beta Glucan (SBG), providing the first evidence explaining the outcome of 3 clinical phase III studies.
Biotec Pharmacon presenting re-established platform at BIO-Europe 2010
Dr Sven Rohmann presented on behalf of Biotec Pharmacon at BIO-Europe Spring 2010 in Barcelona. The presentation took place at March 9, 12:30, under the AutoImmune/Inflammation Section.
